Yang Liu, PhD
Assistant Professor of PathologyCards
Appointments
Contact Info
About
Copy Link
Titles
Assistant Professor of Pathology
Biography
Yang Liu, PhD, was appointed Assistant Professor in the Department of Pathology effective August 1, 2022. Dr. Liu received his PhD degree from the University of California Riverside, working in quite a few different fields, including engineering, chemistry, toxicology, and computer science. He has been a Postdoctoral Research Associate at Yale since 2018 working with Dr. Rong Fan in the Department of Biomedical Engineering at Yale. During the Postdoc training, he developed a high spatial resolution multi-omics sequencing technique, named DBiT-seq, which can achieve near single-cell spatial resolution (10 µm) sequencing of RNA and protein on the same tissue section. He also developed Spatial-CITE-seq (High plex spatial epitome sequencing) and DBiT-seq FFPE technology (spatial transcriptome and epitome of banked FFPE samples). Dr. Liu received the SITC-SU2C Convergence Scholar Awards in 2019 and NIH Hubmap Jumpstart award. His Lab in Yale Pathology will focus on development of spatial based omics techniques (Transcriptome, proteome, epigenome, etc..) and the application of spatial omics techniques to study tumor microenvironments, neurological disease, heart and vascular disease, development and microbiome.
Appointments
Pathology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- PhD
- University of California, Riverside, Environmental Toxicology (2017)
- MS
- University of California, Riverside, Computer Science (2017)
- MS
- Chinese Academy of Science, Analytical Chemistry (2011)
- BS
- Huazhong University of Science & Technology, Computer Science (2008)
- BE
- Huazhong University of Science & Technology, Environmental Engineering (2008)
Research
Copy Link
Overview
Yang Liu, PhD, was appointed Assistant Professor in the Department of Pathology effective August 1, 2022. Dr. Yang Liu received his PhD degree from the University of California Riverside, working in quite a few different fields, including engineering, chemistry, toxicology, and computer science. He has been a Postdoctoral Research Associate at Yale since 2018 working with Dr. Rong Fan in the Department of Biomedical Engineering at Yale. During the Postdoc training, he developed a high spatial resolution multi-omics sequencing technique, named DBiT-seq, which can achieve near single-cell spatial resolution (10 µm) sequencing of RNA and protein on the same tissue section. He also developed Spatial-CITE-seq (High plex spatial epitome sequencing) and DBiT-seq FFPE technology (spatial transcriptome and epitome of banked FFPE samples). Dr. Liu received the SITC-SU2C Convergence Scholar Awards in 2019 and NIH Hubmap Jumpstart award. His Lab in Yale Pathology will focus on development of spatial based omics techniques (Transcriptome, proteome, epigenome, etc..) and the application of spatial omics techniques to study tumor microenvironments, neurological disease, heart and vascular disease, development and microbiome.
ORCIDs
- View Lab Website
Yang Liu Lab
Research at a Glance
Yale Co-Authors
Publications Timeline
Rong Fan, PhD
Mina Xu, MD
Joseph Craft, MD
David A. Hafler, MD, FANA, MSc
Stephanie Halene, MD, Dr Med
Ana Lledo Delgado, MD
Publications
2026
Overall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumab.
Barlin J, Lim P, Pepin J, Hopp E, Cloven N, Eshed H, Black D, Cottrill H, Hand L, O’Malley D, Chuang L, Lee C, Willmott L, Chisamore M, Durbin J, Zheng P, Liu Y, Overesch A, Shpyro S, Monk B. Overall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumab. Journal Of Clinical Oncology 2026, 44: 5511-5511. DOI: 10.1200/jco.2026.44.16_suppl.5511.Peer-Reviewed Original ResearchAltmetricConceptsProgression-free survivalPlatinum-resistant ovarian cancerOverall survivalChemotherapy-free combinationMedian OSOS ratesOvarian cancerStandard-of-care treatment optionMedian progression-free survivalClinically meaningful ORRPlatinum-based therapyDuration of responsePhase 2 trialAnti-tumor activityConfirmed ORRDatabase cutoffMedian DORPeritoneal cancerCTLA-4Adrenal insufficiencyDepleting antibodiesPrimary endpointLast doseSecondary endpointsMechanism of actionOA01.01: Phase 3 Stage 1 Randomized Controlled Trial of Gotistobart vs. Docetaxel in Patients with Metastatic Squamous Cell Lung Cancer who Have Progressed on PD-(L)1 Inhibitors
Cho B, Balaraman R, Chen H, Fawole A, Yu X, Liu Z, Zhang J, Hamm J, Long W, Yang B, Leddon J, Huang Y, Pan P, Shpyro S, Wang Q, Efuni S, Song S, Zheng P, Liu Y, He K, Li T, Socinski M, Wu Y. OA01.01: Phase 3 Stage 1 Randomized Controlled Trial of Gotistobart vs. Docetaxel in Patients with Metastatic Squamous Cell Lung Cancer who Have Progressed on PD-(L)1 Inhibitors. Journal Of Thoracic Oncology 2026, 21: 103740. DOI: 10.1016/j.jtho.2026.103740.Peer-Reviewed Original ResearchAuthor Correction: E3 ligase FBXW7 is critical for RIG-I stabilization during antiviral responses
Song Y, Lai L, Chong Z, He J, Zhang Y, Xue Y, Xie Y, Chen S, Dong P, Chen L, Chen Z, Dai F, Wan X, Xiao P, Cao X, Liu Y, Wang Q. Author Correction: E3 ligase FBXW7 is critical for RIG-I stabilization during antiviral responses. Nature Communications 2026, 17: 2961. PMID: 41912549, PMCID: PMC13035808, DOI: 10.1038/s41467-026-70926-x.Peer-Reviewed Original ResearchGotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
Cho B, Balaraman R, Chen H, Yu X, Fawole A, Liu Z, Zhang J, Wu L, Yang B, Leddon J, Hamm J, Huang Y, Wu L, Pan P, Singh P, Beardsley A, Kayali F, Davarifar A, Lee K, Park K, Lee Y, Li L, Wang X, Sun M, Yu Y, Jain V, Shpyro S, Wang Q, Wenger M, Şahin U, Efuni S, Song S, He K, Zheng P, Liu Y, He K, Li T, Socinski M, Wu Y. Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial. Nature Medicine 2026, 32: 2245-2253. PMID: 41896648, PMCID: PMC13278949, DOI: 10.1038/s41591-026-04323-8.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMetastatic squamous non-small cell lung cancerSquamous non-small cell lung cancerNon-small cell lung cancerCell lung cancerAnti-cytotoxic T-lymphocyte-associated protein 4Lung cancerTreatment-related adverse eventsMedian overall survivalMedian Follow-UpRegulatory T cellsPhase 3 trialClinically meaningful benefitStage 1Metastatic sqNSCLCCTLA-4Overall survivalTumor microenvironmentT cellsPoor prognosisMeaningful benefitAdverse eventsDocetaxelFollow-upGenomic alterationsSqNSCLCSpecific depletion of TIGIThigh CD226− clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting
Zhou H, Li J, Mei S, Zhang M, Zhao H, Yan K, Cheng Y, Zhou Q, Zheng P, Liu Y, Zhang P, Li H, Lu W, Zhang Y. Specific depletion of TIGIThigh CD226− clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. Journal For ImmunoTherapy Of Cancer 2026, 14: e013636. PMID: 41735000, PMCID: PMC12933768, DOI: 10.1136/jitc-2025-013636.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsCD4+ T cellsAntibody-dependent cellular cytotoxicityIntratumoral TregsT cellsTumor-infiltrating CD8+ T cellsTherapeutic efficacyIntratumoral regulatory T cellsCD8+ T cellsNon-small cell lung cancerAntibody-dependent cellular cytotoxicity activitySingle-cell TCR sequencingFlow cytometryT helper cell 1Antitumor activityAnti-TIGIT antibodiesPoor immunotherapy responseTumor-infiltrating lymphocytesRegulatory T cellsEffector cell functionCell lung cancerTumor microenvironment alterationsKnock-In MiceCD226 expressionTIGIT blockadeTreg subsetsAnti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes
Wu Y, Spurrell M, Lledó-Delgado A, Deng S, Wang D, Liu Y, Barkestani M, Perdigoto A, Herold K. Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes. JCI Insight 2026, 11: e192755. PMID: 41574610, PMCID: PMC12892913, DOI: 10.1172/jci.insight.192755.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAnti-CD3 mAb treatmentT cellsMAb treatmentAutoimmune diabetesB cellsCD8+ T cellsIslet-infiltrating T cellsAnti-CD3 monoclonal antibodyT-cell receptor sequencingPrediabetic NOD miceAutoreactive T cellsPancreatic lymph nodesImmune-mediated destructionCourse of treatmentType 1 diabetesInfiltrating TSingle-cell RNAIslet infiltrationMAb-treatedNOD miceLymph nodesEffector functionsOperational toleranceMonoclonal antibodiesProlonged effect
2025
NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma
Ahmed S, DiPersio J, Essell J, Diefenbach C, Perales M, Castilla-Llorente C, Dahiya S, Liu Y, Xu H, Fanton C, Chaudhry S, Lee Z, Marcondes A, Tagliaferri M, Zalevsky J, Miklos D, Turtle C, McGuirk J. NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. Blood Advances 2025, 9: 6092-6095. PMID: 40779552, PMCID: PMC12719151, DOI: 10.1182/bloodadvances.2025016423.Peer-Reviewed Original ResearchCitationsAltmetricSpatial dynamics of brain development and neuroinflammation
Zhang D, Rubio Rodríguez-Kirby L, Lin Y, Wang W, Song M, Wang L, Wang L, Kanatani S, Jimenez-Beristain T, Dang Y, Zhong M, Kukanja P, Bao S, Wang S, Chen X, Gao F, Wang D, Xu H, Ma C, Lou X, Liu Y, Chen J, Sestan N, Uhlén P, Kriegstein A, Zhao H, Castelo-Branco G, Fan R. Spatial dynamics of brain development and neuroinflammation. Nature 2025, 647: 213-227. PMID: 41193846, PMCID: PMC12589135, DOI: 10.1038/s41586-025-09663-y.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBrain developmentPostnatal day 0Chromatin accessibilitySpatial dynamicsTranscription factorsOmics informationMyelin genesDevelopmental processesProjection neuronsNeuroinflammation mouse modelMolecular programsMouse modelDisease-related alterationsTransient activationLesion coreCorpus callosumMultiplexed immunofluorescence imagesSequenceDevelopmental timepointsSpatial remodelingDay 0Mouse brainDynamics of brain developmentImmunofluorescence imagingNeuroinflammationEpigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC Profiling.
Wang D, Di X, Gao F, Li G, Lin L, He S, Zhang D, Jin JY, Liang Y, Cecchini M, Lacy J, Kunstman J, Kunz P, Du J, Liu Y. Epigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC Profiling. BioRxiv 2025 PMID: 41000913, DOI: 10.1101/2025.09.11.675640.Peer-Reviewed Original Research65106 Safety profile of Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, versus Placebo Based on Aggregate Safety Evaluation of 746 Subjects Enrolled Across 9 Studies
Chaudhry S, Gooderham M, Reich A, Gkalpokiotis S, Lee Z, Yu D, Liu Y, Silverberg J, Tagliaferri M, Zalevsky J, Rosmarin D. 65106 Safety profile of Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, versus Placebo Based on Aggregate Safety Evaluation of 746 Subjects Enrolled Across 9 Studies. Journal Of The American Academy Of Dermatology 2025, 93: ab294. DOI: 10.1016/j.jaad.2025.05.1165.Peer-Reviewed Original ResearchConcepts
Academic Achievements & Community Involvement
Copy Link
Honors
honor The HuBMAP Jump Start Award
08/01/2021National AwardNIHDetailsUnited Stateshonor SITC-SU2C Convergence Scholar Awards
09/01/2019National AwardSITC-SU2CDetailsUnited States
News
Copy Link
Get In Touch
Copy Link
Contacts
Locations
Office
Academic Office
300 George Street
New Haven, CT 06511
Lab
Lab
300 George Street
New Haven, CT 06511